Blasts More Than 5 Percent of Bone Marrow Nucleated Cells
4 clinical trials · Condition
◉ Watch Blasts More Than 5 Percent of Bone Marrow Nucleated Cells
| Record | Firm | Date |
|---|---|---|
| Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders (NCT03801434) | William Shomali | 2019-11-15 |
| CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (NCT03896269) | M.D. Anderson Cancer Center | 2019-05-14 |
| Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML (NCT02311998) | M.D. Anderson Cancer Center | 2015-04-16 |
Track Blasts More Than 5 Percent of Bone Marrow Nucleated Cells automatically
Every clearance here is in the API, with alerts when new ones post.